Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
Jim H HughesMitch A PhelpsRichard N UptonStephanie E ReuterYue GaoJohn C ByrdMichael R GreverCraig C HofmeisterGuido MarcucciWilliam BlumKristie A BlumDavid J R FosterPublished in: British journal of clinical pharmacology (2019)
This is the first report of a lenalidomide population pharmacokinetic model to evaluate lenalidomide pharmacokinetics in patients with CLL and compare its pharmacokinetics with other B-cell malignancies. As no differences in pharmacokinetics were found between the observed cancer-types, the unique toxicities observed in CLL may be due to disease-specific pharmacodynamics.